Heron wins patent lawsuit against Fresenius Kabi over CINVANTI; generic blocked until 2035

HERON THERAPEUTICS, INC. /DE/

Court ruled Heron's U.S. Patent Nos. 9,561,229 and 9,974,794 valid and infringed by Fresenius Kabi's proposed generic CINVANTI.
Effective date of any FDA approval for Fresenius Kabi's ANDA cannot be earlier than September 18, 2035 (patent expiration).
Ruling follows partial summary judgment for infringement in May 2024 and four-day bench trial in June 2024.
Heron will submit proposed final judgment by December 9, 2024.
This protects CINVANTI revenue from generic competition until patents expire in 2035.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.